Finasteride and 5-Alpha-Reductase: The Oral Label, the Topical Literature, and the FDA Alert

Finasteride is the oldest small molecule in a modern hair protocol and the one with the most regulatory paper attached to it. An approved oral product has carried an FDA label for male pattern hair loss since the late 1990s, the label has been revised more than once as the adverse event record grew, no topical finasteride product has ever been approved, and in April 2025 the FDA alerted providers, compounders and consumers to adverse event reports for the compounded topical form. A practice that sources finasteride in either form is sourcing something that has been argued about in print for three decades, and the argument is worth knowing.

This article sets out the mechanism, what the approved label states, what the systematic reviews and the network meta-analyses report for the oral tablet, what the topical literature reports and what it does not create, and what the FDA and the European Medicines Agency have said in the last two years. It is written for practitioners and practice operators, it attributes every finding to the study or the agency that reported it, and it makes no claim about what finasteride does to any patient. The counselling conversation belongs to the prescriber, and this article says so more than once because the FDA alert suggests it has been skipped.

The enzyme is a currency exchange, and the follicle pays in dihydrotestosterone

Testosterone circulates widely, but the androgen the scalp follicle responds to most strongly is dihydrotestosterone, and the conversion between the two is done by 5-alpha-reductase. An analogy that holds for the timing and not for the chemistry is a currency exchange at a border: testosterone arrives in one currency, the enzyme converts it, and the follicle is paid in the local one. In a genetically susceptible follicle, the dermal papilla responds to that payment by shortening the growth phase over successive cycles until the follicle miniaturises, which is the process the literature calls androgenetic alopecia. The Cold Spring Harbor review by Lim and Nusse describes the Wnt signalling that the papilla uses to call the growth phase, and it is the signal that androgen exposure disrupts.

The enzyme exists as two principal isoforms. Type I predominates in sebaceous glands and skin; type II predominates in the prostate and in the dermal papilla of scalp follicles. Finasteride inhibits type II selectively, and the approved label describes a reduction in scalp and serum dihydrotestosterone as its pharmacodynamic effect. That selectivity is why finasteride was developed first for the prostate and why the one-milligram hair strength and the five-milligram prostate strength are the same molecule at different exposures.

The approved label says who, how long, and what to watch

The approved one-milligram oral product is indicated, in the words of its label, for male pattern hair loss in men only. The label states that daily use for three months or more is generally necessary before benefit is observed and that continued use is recommended to sustain it, and it states that the product is not indicated for women or children. It carries a pregnancy contraindication and a warning about exposure of pregnant women to crushed or broken tablets, and it describes the effect of finasteride on prostate-specific antigen measurements, which matters to any man whose prostate is being monitored.

The label was revised in 2012 to describe sexual adverse reactions that persisted after the product was discontinued, and the current prescribing information lists depression and suicidal ideation among the adverse events reported. All of that is reproduced in full on DailyMed and in the 2012 revised label on the FDA site, both cited below. A supplier can state what the label says and where to read it; a prescriber reads it with a patient in the room.

The five-milligram tablet is approved for benign prostatic hyperplasia. The oral tablet reaches a patient as the FDA-approved product under an ordinary prescription, and the compounded formulations this site describes are limited to topical scalp solutions prepared to an individual prescription. Iamsumang and colleagues reviewed in 2020 the evidence for finasteride in female pattern hair loss, an off-label question that this article does not resolve and that the European S3 guideline addresses directly.

The oral tablet has meta-analyses, guidelines and a network ranking behind it

The 2017 systematic review and meta-analysis by Adil and Godwin in the Journal of the American Academy of Dermatology pooled randomised trials of the three most studied interventions for androgenetic alopecia and reported that oral finasteride, topical minoxidil and low-level laser light each outperformed placebo on hair count. It is the reference most often cited for the position that the approved actives have trial evidence behind them.

A 2022 network meta-analysis by Gupta and colleagues in JAMA Dermatology ranked minoxidil and the 5-alpha-reductase inhibitors against one another in men, and a 2025 analysis by the same group in the Journal of Cosmetic Dermatology compared the monotherapies again with newer trials included. Starace and colleagues compared topical minoxidil, oral finasteride and topical finasteride as monotherapies in 2024. The European S3 guideline by Kanti and colleagues, published in 2018, gave oral finasteride a formal evidence-graded recommendation in men and set out its position on women, and a 2025 Canadian consensus by Landells and colleagues restated the specialist approach. Devjani and colleagues in Drugs in 2023 and Nestor and colleagues in 2021 provide the current therapy updates a reader wants beside those rankings, and Nestor is the one that discusses compliance, cost and ethics in the same breath as efficacy.

The topical literature is real, and it does not create an approved product

The rationale for topical finasteride is that scalp dihydrotestosterone can be lowered with less systemic exposure than the oral tablet produces, and Suchonwanit and colleagues reviewed that rationale in 2022 before the phase III data published. The phase III trial itself, by Piraccini and colleagues in the Journal of the European Academy of Dermatology and Venereology in 2022, studied a 0.25% finasteride spray solution in men and reported target-area hair count gains over vehicle at 24 weeks, with serum dihydrotestosterone reductions smaller than those reported for the oral tablet.

A 2025 systematic review and meta-analysis in Frontiers in Medicine pooled seven randomised trials, 396 participants in total, comparing a mixed minoxidil and finasteride solution with minoxidil solution alone, and reported that the combination outperformed minoxidil alone on hair density, hair diameter and global photographic assessment. The compounded solutions on this site pair 0.1% finasteride with 5% minoxidil, a lower finasteride concentration than the phase III spray, which is one of several reasons a trial result does not transfer to a compounded product without evidence that it does.

None of that creates an approved product. No topical finasteride formulation is FDA-approved, and a compounded topical solution is prepared under section 503A to an individual prescription without FDA review of its safety, effectiveness or quality. The FDA’s own questions and answers on compounding, cited below, say exactly that, and every page on this site that mentions topical finasteride links the alert that follows.

The FDA alert is about counselling as much as pharmacology

The sentence in the alert with the most operational content for a practice is the one about what patients were told. The FDA recorded that many of the consumers in those reports stated they had not been told of the potential risks by the prescriber, and that some had been told the topical form carried none. That is a counselling finding rather than a pharmacological one, and it is the reason this article repeats that the counselling conversation belongs to the prescriber and to the approved label.

Two pharmacovigilance analyses of the same reporting system were published in 2025. Zhong and colleagues in PLoS One analysed finasteride reports from 2004 to April 2024 across organ systems, and Thaibah and colleagues in Pharmaceuticals examined suicidality signals specifically; Gupta and colleagues evaluated the depression and suicide question separately in the Journal of Cosmetic Dermatology. All three are analyses of spontaneous reports rather than of trial data, which is a different kind of evidence with a different set of limitations, and the evidence page on finasteride under the Science section of this site labels each citation with its study design for that reason. The European Medicines Agency, in May 2025, added suicidal ideation to the product information for finasteride and required a patient card to accompany it.

What a practice can source, and in which regime

Finasteride reaches a practice in two materially different forms. The oral tablet is an FDA-approved product dispensed against an ordinary prescription, and the topical form appears as a fraction of a percent in two minoxidil solutions that our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, prepares to an individual prescription with a short beyond-use date and a single-unit ceiling per fill. Compounded preparations are dispensed only in the states where the pharmacy holds a non-resident license, and the state hair guides on this site say which states those are.

The table records what exists and what has been studied. It is not a recommendation of any row over another, and a practice choosing between rows is making a prescribing decision that this site takes no part in.

Closing Observation

Finasteride is the component of a hair protocol whose evidence and whose warnings arrived together, and the two have never been separable. The oral tablet has an approved label, pooled randomised trials and a network ranking behind it, and it also has a 2012 label revision, two 2025 pharmacovigilance analyses and a European product-information update that name persistent sexual and psychiatric adverse events. The topical form has a phase III trial and a meta-analysis of combination solutions behind it, and it also has an FDA alert whose central finding is that patients were not told what the oral literature already said.

What the literature does not support is the shortcut the market takes next, which is to present the topical form as the oral tablet without the oral tablet’s warnings. A practice that holds both halves of the record will source finasteride in the form the prescriber specifies, will keep the oral and topical line items apart, will send every patient to the approved label and the alert, and will be considerably harder to sell a solution to on the strength of the word topical.